18th Sep 2012 14:36
Vectura Group plc
Results of the Annual General Meeting held on 18 September 2012
Chippenham, UK, 18 September 2012: Vectura Group plc (LSE: VEC) announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed by shareholders.
All resolutions were approved on a poll. The results of the poll are set out below.
Resolution | Total votes for (including discretionary votes)* | % | Total votes against* | % | Total votes cast (excluding votes withheld) | Votes withheld | |
1 | To receive the Report & Accounts | 251,269,330
| 99.67 | 838,246
| 0.33 | 252,107,576
| 371,770
|
2 | To approve the Report on remuneration | 245,155,337 | 99.57 | 1,059,676
| 0.43 | 246,215,013
| 6,264,333
|
3 | To elect Dr Trevor Phillips | 252,048,930 | 99.88
| 304,508
| 0.12 | 252,353,438
| 125,394
|
4 | To re-elect Dr Susan Foden | 252,089,511 | 99.89 | 265,415
| 0.11 | 252,354,926
| 124,420
|
5 | To re-elect Dr John Brown | 252,084,380 | 99.89 | 265,545
| 0.11 | 252,349,925
| 129,421
|
6 | To re-elect Mr Jack Cashman | 251,483,510 | 99.89
| 270,435
| 0.11 | 251,753,945
| 124,420
|
7 | To re-appoint Deloitte LLP | 251,514,682 | 99.67
| 840,972
| 0.33 | 252,355,654
| 123,692
|
8 | To authorise the Director's to determine auditor's remuneration | 252,222,480 | 99.94
| 145,463
| 0.06 | 252,367,943
| 111,403
|
9 | To authorise the Directors to allot shares | 252,284,948 | 99.97
| 81,881
| 0.03 | 252,366,829
| 112,517
|
10 | To approve Long-Term Incentive Plan | 248,711,399 | 99.93
| 169,512
| 0.07 | 248,880,911
| 3,598,435
|
11 | To authorise the Directors to allot equity securities | 248,807,217 | 99.44
| 1,399,978
| 0.56 | 250,207,195
| 2,272,151
|
12 | To authorise the Directors' authority to call general meetings | 246,991,738 | 97.88
| 5,351,035
| 2.12 | 252,342,773
| 139,519
|
*NB: The percentage of votes cast for and against excludes withheld votes.
The Company confirms that copies of all resolutions passed at the Annual General Meeting held earlier today, Tuesday 18 September 2012, will be submitted to the National Storage Mechanism (NSM) at www.hemscott.com/nsm.co and will shortly be available for viewing.
- Ends -
Enquiries:
Vectura Group plc | +44 (0)1249 667700 |
Chris Blackwell, Chief Executive | |
Anne Hyland, Chief Financial Officer | |
Dr Karl Keegan, Corporate Development Director | |
FTI Consulting | +44 (0)20 7831 3113 |
Ben Atwell | |
Susan Stuart Simon Conway |
Notes for Editors:
About Vectura
Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn.
Vectura has six products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK).
Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. For further information, please visit Vectura's website at www.vectura.com
Related Shares:
VEC.L